Page 17 - Pharmaceutical Firms

ED raids pharma firm Parabolic Drugs, promoters in money laundering probe

The Enforcement Directorate on Friday carried out raids at multiple premises of Chandigarh-based pharmaceutical company Parabolic Drugs and its promoters as part of a money laundering investigation linked to an alleged bank loan fraud case, official sources said. The searches by the central agency covered a total of 17 premises in Delhi, Mumbai, Chandigarh and Panchkula and Ambala in Haryana, they said. The action is being undertaken under the provisions of the Prevention of Money Laundering Act (PMLA) and the ED case stems from a 2021 CBI FIR against the company and its promoters Vineet Gupta and Pranav Gupta among others, the sources said. The agency, as per the sources, is also looking at some documents from Sonepat-based Ashoka University as two directors of the company, Vineet Gupta and Pranav Gupta, have been associated with the educational institution in the past. The two had stepped down from all the boards and committees of the university in 2022, days after the CBI ...

Fewer generics enter market after linagliptin's patent expiry this August

When Sitagliptin went off patent, nearly 200 brands were vying for a share of the market

2,350 acres set aside for pharma and medical parks in Uttar Pradesh

Chief Minister Yogi Adityanath has envisioned increasing the state's contribution to the pharma industry from 2 per cent to 10-12 per cent

Sun Pharma recalls 144 bottles of anti-depression drug from US market

Sun Pharmaceutical Industries Inc has recalled 144 bottles of a generic anti-depression medicine from the US market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA). The US-based subsdiary of the Mumbai-headquartered drug company initiated the recall for the affected lot of Bupropion Hydrochloride extended-release tablets due to "failed dissolution specifications,", the US health regulator said in its latest Enforcement Report. The affected lot was manufactured at Sun Pharma's Halol-based plant in Gujarat and was distributed in the US by Sun Pharmaceutical Industries Inc, based in Princeton, New Jersy, it said. Bupropion is a medication commonly used to treat depression. The US-based drug maker initiated the voluntary Class III nationwide (US) recall on October 4 this year. As per the US FDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health ...

Glenmark Pharma launches triple-combination drug for Type 2 Diabetes

Medication will be sold under the brand name Zita DM, will be priced at Rs 14 per tablet

PLI scheme effect? Bulk drug imports from China slow, shows data

Experts say scheme to boost local manufacturing will take 5-7 years to show tangible results

Glenmark gets USFDA nod to market generic version of Otezla tablets

Glenmark's current portfolio includes a total of 188 products that have been authorised for distribution in the US marketplace

Zydus Lifesciences appoints Punit Patel as president & CEO of Americas

Punit Patel will oversee the business operations of all Zydus entities in North America, including generics, injectables, specialty business, rare and orphan disease portfolio

Pharma result preview: US stable, India muted in the second quarter

Hospital occupancy rates rise 200-400 bps, while diagnostic sector sees seasonal benefits

FDA has accepted NDA for dermatological drug Deuruxolitinib: Sun Pharma

Sun Pharmaceutical Industries Ltd said that it had submitted an 8mg twice-daily regimen of deuruxolitinib for FDA review

Apotex seeks $118 million from Panacea for collaboration pact breach

Canada-based Apotex Inc has sought USD 118.14 million from Panacea Biotec over breach of a collaboration agreement inked in 2014, the capital-based drug firm said on Thursday. The company has received a notification dated October 4 from the International Court of Arbitration, Paris, intimating that an arbitration proceeding has been initiated as per a request by Apotex Inc, Panacea Biotec said in a regulatory filing. Apotex has alleged that the company has breached its obligations under the collaboration agreement for research, development, licence, supply and sale of products inked on May 9, 2014, it added. Apotex has alleged that there has been a purported delay in seeking approval from US Food and Drug Administration for the product mentioned in the said agreement, Panacea Biotec said. "Apotex has claimed USD 118.14 million towards outsized alleged losses plus interest thereon to the extent permissible under the applicable law," it added. The company believes it is not in breac

Stride Pharma Global receives USFDA approval or Efavirenz, other drugs

The company aims to launch about 60 new products in the next three years in the US market

Schedule M likely to be revised to bring it closer to WHO standards

The draft rules, still under consideration, include provisions to strengthen quality control and the safety of drugs manufactured in India

Medicine to manufacturing: Nano is the next frontier in 3D printing

Nano-level 3D printing can have various uses in medicine, like growing tissue cells to regenerate organs. Nano robots in bodies can attack cancer cells

Suven Pharma gets a new board as Advent International completes stake buy

Advent had announced the acquisition of a significant stake in Suven Pharma in December of the previous year from the Jasti family

Glenmark, Cosmo partner to bring acne treatment Winlevi to Europe, S Africa

This agreement grants Glenmark the exclusive right to commercialise Winlevi in 15 EU countries, South Africa, and the UK

Glenmark announces license agreements for Winlevi in Europe and S Africa

Cassiopea, a subsidiary of Cosmo, will receive an upfront payment of $5 million and agreed double-digit royalties on net sales

Pharma sector must focus on innovation to become global leader: Minister

Union health minister Mansukh Mandaviya on Tuesday asked domestic pharmaceutical industry to focus on the research and development of innovative products to move up the value chain and achieve global leadership. Mandaviya, who also holds the Chemical and Fertilisers portfolio, asked medical technology companies to produce critical equipment in India for the global markets. While formally unveiling the National Policy on Research & Development and Innovation in the Pharma-Med Tech Sector here, Mandaviya said the domestic pharmaceutical companies invest less on research and development when compared to multinational companies. "International MNCs spend 20-25 per cent of their profits in research and innovation while for Indian companies the average is around 10 per cent...Till the time we do not come out with research-led innovative products, we cannot lead the segment globally," he noted. He said the government wants to make the pharma industry self-reliant by 2047. "Today is a ...

Pharmaceutical firm Valiant Laboratories' IPO to open on September 27

Pharmaceutical ingredient manufacturing firm Valiant Laboratories has decided to launch its initial share sale for public subscription on September 27. The Initial Public Offering (IPO), which is an entirely fresh issuance of 1.08 crore equity shares with no offer for sale component, will be concluded on October 3, according to the red herring prospectus filed with Sebi on Friday. Further, bidding for anchor investors will open on September 26. Proceeds of the issue will be utilised to set up a manufacturing facility for speciality chemicals in Gujarat through its subsidiary -- Valiant Advanced Sciences Private Ltd. -- and to meet the working capital requirements of the subsidiary company. Valiant Laboratories is an active pharmaceutical ingredient or bulk drug manufacturing company with its focus on manufacturing paracetamol, which is used in the treatment of headache, muscle ache, arthritis, backache, toothache, cold and fever. The paracetamol API industry grew from Rs 2,200 cr

Lupin acquires five legacy brands from Meranini to solidify its portfolio

Lupin has already been marketing these brands in India since July 2021 under an agreement with A Menarini India Private Limited but will now have the full trademark ownership of the five brands